Skip to content

Effect on cognitive function by ingesting foods containing plasmalogen-containing phospholipids derived from porcine brain (preliminary study, safety evaluation)

Effect on cognitive function by ingesting foods containing plasmalogen-containing phospholipids derived from porcine brain (preliminary study, safety evaluation): single blinded study - Effect on cognitive function by ingesting foods containing plasmalogen-containing phospholipids derived from porcine brain (preliminary study, safety evaluation)

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000050775
Enrollment
24
Registered
2023-05-30
Start date
2023-05-30
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy adult

Interventions

Take the test article 2 tablets daily for 12 weeks Take the test article 3 tablets daily for 12 weeks Take the test article 15 tablets daily for 4 weeks

Sponsors

Japan Clinical Trial Association
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Subjects who do not have dementia but are aware of age-related decline in cognitive function

Exclusion criteria

Exclusion criteria: 1.Subjects who are judged to have dementia, those who are receiving treatment, medication, and lifestyle guidance from a doctor due to dementia, those who have received it in the past 2.Subjects with MMSE score of 23 or less 3.Subjects with serious cerebrovascular disease, heart disease, liver disease, kidney disease, digestive system disease, infectious diseases that require notification, etc. 4.Subjects with food allergies 5.Subjects who are pregnant or lactating 6.Subjects who consume medicinal product which may influence the outcome of the study 7.Subjects who consume food which may influence the outcome of the study 8.Subjects who are judged as unsuitable for the study by the investigator for the other reason

Design outcomes

Primary

MeasureTime frame
WMS-R, blood test

Countries

Japan

Contacts

Public ContactTakeshi Kaneko

Japan Clinical Trial Association N.A.

info@yakujihou.org0364574666

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026